FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4310355937> ?p ?o ?g. }

• W4310355937 endingPage "38" @default.
• W4310355937 startingPage "30" @default.
• W4310355937 abstract "AIM: to compare long-term outcomes and safety of the addition of paclitaxel to chemoradiotherapy for squamous cell anal carcinoma. PATIENTS AND METHODS : A prospective phase 3 randomized trial included patients with histologically verified non-metastatic anal squamous cell carcinoma. Patients received radiotherapy 52-54 Gy (for T1-T2 tumors) and 56-58 Gy (for T3- T4 tumors) in 2 Gy daily fractions during chemotherapy with mitomycin C (10 mg/m 2 i.v. day 1), capecitabine (625 mg/m 2 2 times a day orally on days of radiation therapy), paclitaxel (45 mg/m 2 i.v. on days 3, 10 , 17, 24, 31) during 2013-2019. In the control group patients received a similar course of RT and chemotherapy with mitomycin C (12 mg/m 2 i.v. day 1 ), capecitabine (825 mg/m 2 2 times a day orally on radiotherapy days). The primary endpoint was 3-year disease-free survival (DFS). Secondary endpoints included complication rate (NCI-CTCAE 4.0), complete clinical response rate at 12 weeks and 26 weeks after completion of CRT, and 3-year overall survival (OS). RESULTS: The study and control groups included 72 patients each. The median follow-up was 39.5 months. A complete clinical response at the 26-week follow-up was recorded in 64 (88.9%) patients in the study group and in 54 (75%) patients in the control group (p=0.049). There were no differences in the incidence of complications of grades 3-4 in the two groups (39/72 [54.2%] in the study group versus 35/72 [48.6%] in the control group (p=0.617)). Three-year progression-free survival in the study group was 87.1%, in the control group - 64.4% (p=0.001). Three-year overall survival in the study group was 95.5%, in the control group - 80.0% (p<0.001). CONCLUSION: CRT with paclitaxel for squamous cell anal carcinoma has acceptable toxicity and may improve long-term treatment outcomes." @default.
• W4310355937 created "2022-12-09" @default.
• W4310355937 creator A5017012952 @default.
• W4310355937 creator A5030197564 @default.
• W4310355937 creator A5043796563 @default.
• W4310355937 creator A5045813336 @default.
• W4310355937 creator A5047784026 @default.
• W4310355937 creator A5071104988 @default.
• W4310355937 creator A5080144973 @default.
• W4310355937 creator A5083782912 @default.
• W4310355937 date "2022-12-21" @default.
• W4310355937 modified "2023-10-01" @default.
• W4310355937 title "The addition of paclitaxel in chemoradiotherapy of anal squamous cell carcinoma: a prospective randomized phase 3 trial" @default.
• W4310355937 cites W1550298324 @default.
• W4310355937 cites W1898337686 @default.
• W4310355937 cites W1964704839 @default.
• W4310355937 cites W1972221735 @default.
• W4310355937 cites W1994934546 @default.
• W4310355937 cites W2002002528 @default.
• W4310355937 cites W2016200608 @default.
• W4310355937 cites W2071719050 @default.
• W4310355937 cites W2146819169 @default.
• W4310355937 cites W2158244375 @default.
• W4310355937 cites W2164644812 @default.
• W4310355937 cites W2792399788 @default.
• W4310355937 cites W2793049599 @default.
• W4310355937 cites W2981726708 @default.
• W4310355937 cites W3004950999 @default.
• W4310355937 cites W3135047168 @default.
• W4310355937 cites W3215186548 @default.
• W4310355937 doi "https://doi.org/10.33878/2073-7556-2022-21-4-30-38" @default.
• W4310355937 hasPublicationYear "2022" @default.
• W4310355937 type Work @default.
• W4310355937 citedByCount "0" @default.
• W4310355937 crossrefType "journal-article" @default.
• W4310355937 hasAuthorship W4310355937A5017012952 @default.
• W4310355937 hasAuthorship W4310355937A5030197564 @default.
• W4310355937 hasAuthorship W4310355937A5043796563 @default.
• W4310355937 hasAuthorship W4310355937A5045813336 @default.
• W4310355937 hasAuthorship W4310355937A5047784026 @default.
• W4310355937 hasAuthorship W4310355937A5071104988 @default.
• W4310355937 hasAuthorship W4310355937A5080144973 @default.
• W4310355937 hasAuthorship W4310355937A5083782912 @default.
• W4310355937 hasBestOaLocation W43103559371 @default.
• W4310355937 hasConcept C121608353 @default.
• W4310355937 hasConcept C126322002 @default.
• W4310355937 hasConcept C141071460 @default.
• W4310355937 hasConcept C168563851 @default.
• W4310355937 hasConcept C203092338 @default.
• W4310355937 hasConcept C2776694085 @default.
• W4310355937 hasConcept C2777292972 @default.
• W4310355937 hasConcept C2777546739 @default.
• W4310355937 hasConcept C2777909004 @default.
• W4310355937 hasConcept C2778424827 @default.
• W4310355937 hasConcept C2779338040 @default.
• W4310355937 hasConcept C31760486 @default.
• W4310355937 hasConcept C509974204 @default.
• W4310355937 hasConcept C526805850 @default.
• W4310355937 hasConcept C71924100 @default.
• W4310355937 hasConcept C90924648 @default.
• W4310355937 hasConceptScore W4310355937C121608353 @default.
• W4310355937 hasConceptScore W4310355937C126322002 @default.
• W4310355937 hasConceptScore W4310355937C141071460 @default.
• W4310355937 hasConceptScore W4310355937C168563851 @default.
• W4310355937 hasConceptScore W4310355937C203092338 @default.
• W4310355937 hasConceptScore W4310355937C2776694085 @default.
• W4310355937 hasConceptScore W4310355937C2777292972 @default.
• W4310355937 hasConceptScore W4310355937C2777546739 @default.
• W4310355937 hasConceptScore W4310355937C2777909004 @default.
• W4310355937 hasConceptScore W4310355937C2778424827 @default.
• W4310355937 hasConceptScore W4310355937C2779338040 @default.
• W4310355937 hasConceptScore W4310355937C31760486 @default.
• W4310355937 hasConceptScore W4310355937C509974204 @default.
• W4310355937 hasConceptScore W4310355937C526805850 @default.
• W4310355937 hasConceptScore W4310355937C71924100 @default.
• W4310355937 hasConceptScore W4310355937C90924648 @default.
• W4310355937 hasIssue "4" @default.
• W4310355937 hasLocation W43103559371 @default.
• W4310355937 hasOpenAccess W4310355937 @default.
• W4310355937 hasPrimaryLocation W43103559371 @default.
• W4310355937 hasRelatedWork W1983052552 @default.
• W4310355937 hasRelatedWork W2107653012 @default.
• W4310355937 hasRelatedWork W2131688297 @default.
• W4310355937 hasRelatedWork W2165410491 @default.
• W4310355937 hasRelatedWork W2367812775 @default.
• W4310355937 hasRelatedWork W2386824526 @default.
• W4310355937 hasRelatedWork W2390066975 @default.
• W4310355937 hasRelatedWork W2404633042 @default.
• W4310355937 hasRelatedWork W3183798157 @default.
• W4310355937 hasRelatedWork W4308718010 @default.
• W4310355937 hasVolume "21" @default.
• W4310355937 isParatext "false" @default.
• W4310355937 isRetracted "false" @default.
• W4310355937 workType "article" @default.